Table 1.
Patient's characteristics at the moment of dosing biologic drug level.
| Biologic agent | Current biologic treatment, duration, and mean | DAS28 baseline, mean | SDAI baseline, mean | csDMARD associated, no (%) | ACPA positive, no (%) | RF positive, no (%) |
|---|---|---|---|---|---|---|
| RTX | ||||||
| Group A | 48.8 ± 53.4 | 3.65 ± 1.12 | 20.0 ± 15.7 | 15 (60%) | 14 (56%) | 16 (64%) |
| Group B | 27.7 ± 13.7 | 3.45 ± 1.19 | 21.7 ± 29.6 | 8 (32%) | 4 (16%) | 7 (28%) |
| P | 0.294 | 0.678 | 0.845 | 0.667 | 0.021 | 0.049 |
| IFX | ||||||
| Group A | 40.6 ± 39.9 | 3.57 ± 1.25 | 15.2 ± 19.7 | 6 (30%) | 4 (20%) | 7 (35%) |
| Group B | 29.3 ± 17.5 | 5.42 ± 1.19 | 43.2 ± 29.6 | 6 (30%) | 3 (15%) | 4 (20%) |
| P | 0.379 | 0.003 | 0.026 | 0.582 | 0.515 | 0.064 |
| ETN | ||||||
| Group A | 47.8 ± 38.5 | 4.14 ± 1.44 | 31.6 ± 31.3 | 10 (55.55%) | 11 (61.11%) | 12 (66.67%) |
| Group B | 57.6 ± 23.7 | 5.25 ± 1.79 | 41.5 ± 40.3 | 3 (16.67%) | 2 (11.11%) | 2 (11.11%) |
| P | 0.679 | 0.259 | 0.639 | 0.239 | 0.814 | 0.612 |
| ADL | ||||||
| Group A | 46.7 ± 25.2 | 3.39 ± 1.04 | 10.1 ± 6.05 | 7 (77.78%) | 4 (44.44%) | 6 (66.67%) |
| Group B | 36 | 3.54 | 32.9 | 1 (11.11%) | 1 (11.11%) | 1 (11.11%) |
| P | 0.700 | 0.902 | 0.009 | 0.708 | 0.495 | 0.571 |
Differences between patient's baseline characteristics were tested by Student's t-test or chi-square test.
RTX: rituximab; IFX: infliximab; ETN: etanercept; ADL: adalimumab.
Group A: detectable drug level; Group B: undetectable drug level.
csDMARD: conventional synthetic disease modifying antirheumatic drug; ACPA: anticitrullinated peptides antibodies status; RF: rheumatoid factor status.